Lexaria Regains Nasdaq Compliance, Delisting Hearing Cancelled
LEXX has more than doubled off its 52-week low of $4.21.
Summary
Lexaria Bioscience received confirmation from Nasdaq that it has regained compliance with the minimum bid price rule, cancelling the delisting hearing and securing its continued listing on the Nasdaq Capital Market.
Key Events · Legal and Risk Events · LEXX
-
Nasdaq Compliance Regained
Nasdaq confirmed Lexaria has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).
-
Delisting Hearing Cancelled
The previously requested Nasdaq hearing has been cancelled, and the company's common stock will continue to be listed and trading on the Nasdaq Capital Market.
-
Reverse Split Impact
The 1-for-15 reverse stock split effective August 3, 2026, was the primary mechanism that lifted the share price above the $1.00 threshold, enabling this compliance confirmation.
-
Going Concern Context
This listing reprieve comes amid a going-concern warning and cash runway only into early 2027, as disclosed in the July 13 10-Q.
Analysis · LEXX · Life Sciences
Lexaria has cured the Nasdaq minimum bid price deficiency that triggered a delisting notice on August 10. The hearing is cancelled and the stock will continue trading on the Nasdaq Capital Market. This removes a major overhang for a company already facing going-concern warnings and a cash runway only into early 2027. The reverse split executed on August 3 was the primary driver of the price recovery, and this confirmation solidifies the company's listing status.
At the time of this filing, LEXX was trading at $9.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $4.21 to $23.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.